周五盘中，Kalvista Pharmaceuticals Inc（KALV）股价大跌5.53%，引发市场关注。这一跌势与公司同日发布的2025财年财报密切相关。
根据Kalvista Pharmaceuticals公布的财报，公司2025财年净亏损达1.83亿美元，同比扩大44.09%。更令投资者担忧的是，公司报告期内营业收入为零，每股基本亏损3.69美元。这些数据表明公司目前面临严峻的财务挑战。
财报还揭示了公司的资产负债状况。Kalvista Pharmaceuticals总负债为1.55亿美元，资产负债比高达1.62，流动比率仅为0.06，反映出公司当前的财务状况不容乐观。尽管如此，华尔街分析师对公司前景仍保持谨慎乐观，9家机构给出的目标价均值为30.89美元，最高目标价达40美元。Kalvista Pharmaceuticals作为一家专注于开发小分子蛋白酶抑制剂的制药公司，其产品管线主要针对遗传性血管性水肿和糖尿病性黄斑水肿等疾病，公司的未来发展仍值得市场关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.